ANCA-associated vasculitis (AAV) is an autoimmune disease that causes inflammation and damage to blood vessels, affecting organs like the kidneys, lungs, and skin. This clinical trial aims to assess the long-term safety of study drug, a medication that reduces inflammation by targeting specific immune pathways. Participants will take study drug over time to evaluate its effectiveness in managing AAV and preventing organ damage, helping researchers understand its role in maintaining disease remission.
